AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39665588 — intervention group
Group type: EXPERIMENTAL
Intervention: Active monitoring (AM)
Number of subjects: 957
Study 39665621 — intervention group
Group type: EXPERIMENTAL
Intervention: CHIP
Number of subjects: 446
Study 39665621 — intervention group
Group type: EXPERIMENTAL
Intervention: mLOY
Number of subjects: 446
Study 39665633 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-phase CT
Number of subjects: 8893
Study 39665633 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory CT
Number of subjects: 8893
Study 39665633 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory CT
Number of subjects: 8893
Study 39665633 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data
Number of subjects: 8893
Study 39665649 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of axillary surgery (surgery-omission group)
Number of subjects: 4858
Study 39665649 — intervention group
Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (surgery group)
Number of subjects: 4858
Study 39665652 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedaquiline monotherapy for 8 weeks
Number of subjects: 9
Study 39665652 — intervention group
Group type: COMPARATOR
Intervention: Standard multidrug therapy (as defined by the World Health Organization) after 8 weeks of bedaquiline
Number of subjects: 9
Study 39665701 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 6001
Study 39665701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6001
Study 39665734 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls only
Number of subjects: 508
Study 39665734 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls+mHealth
Number of subjects: 508
Study 39665734 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls+NRT
Number of subjects: 508
Study 39665734 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls+NRT+mHealth
Number of subjects: 508
Study 39665734 — intervention group
Group type: COMPARATOR
Intervention: No-mailed NRT
Number of subjects: 508
Study 39665734 — intervention group
Group type: COMPARATOR
Intervention: Mailed NRT
Number of subjects: 508
Study 39665734 — intervention group
Group type: COMPARATOR
Intervention: Mailed NRT vs No-mailed NRT
Number of subjects: 508
Study 39665734 — intervention group
Group type: COMPARATOR
Intervention: mHealth vs No mHealth
Number of subjects: 508
Study 39665770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG) 10 mg/kg on days 1 and 8 of a 21-day cycle
Number of subjects: 43
Study 39665869 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% cholic acid (CA)-supplemented chow for 7 days
Number of subjects: 76
Study 39665869 — intervention group
Group type: EXPERIMENTAL
Intervention: PIZZ subjects
Number of subjects: 76
Study 39665869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocytes with AAT aggregates
Number of subjects: 76
Study 39665869 — intervention group
Group type: EXPERIMENTAL
Intervention: PiZ overexpression in cultured cells/primary hepatocytes
Number of subjects: 76
Study 39665869 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 subjects)
Number of subjects: 76
Study 39666075 — intervention group
Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 115
Study 39666075 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 115
Study 39666075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TKA and UKA
Number of subjects: 115
Study 39666143 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab treatment
Number of subjects: 1072
Study 39666249 — intervention group
Group type: EXPERIMENTAL
Intervention: Clareon CNA0T0 intraocular lens (IOL)
Number of subjects: 49
Study 39666256 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate DOAC dosing
Number of subjects: 866
Study 39666256 — intervention group
Group type: EXPERIMENTAL
Intervention: DOAC underdosing predictors
Number of subjects: 866
Study 39666256 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct DOAC dosing predictors
Number of subjects: 866
Study 39666392 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfection group (3 exposures to 20 male cercariae)
Number of subjects: 24
Study 39666392 — intervention group
Group type: COMPARATOR
Intervention: Infection control group (2 mock exposures with water)
Number of subjects: 24
Study 39666392 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfection group
Number of subjects: 24
Study 39666392 — intervention group
Group type: COMPARATOR
Intervention: Infection control group
Number of subjects: 24
Study 39666392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 39666396 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 booster dose
Number of subjects: 3793
Study 39666396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3793
Study 39666396 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 primary series
Number of subjects: 3793
Study 39666396 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 3793
Study 39666443 — intervention group
Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 84
Study 39666443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 39666490 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one music therapy (MT) intervention for 16 weeks
Number of subjects: 42
Study 39666490 — intervention group
Group type: COMPARATOR
Intervention: Active control group receiving storytelling
Number of subjects: 42
Study 39666517 — intervention group
Group type: EXPERIMENTAL
Intervention: VIA Family
Number of subjects: 95
Study 39666517 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 95
Study 39666578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline nasal irrigation and gargling (HSNIG) with a 2.6% hypertonic saline solution.
Number of subjects: 576
Study 39666578 — intervention group
Group type: COMPARATOR
Intervention: Control group performing ablution for Muslim prayers (wudu) with tap water.
Number of subjects: 576
Study 39666696 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Number of subjects: 28
Study 39666696 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercises
Number of subjects: 28
Study 39666696 — intervention group
Group type: COMPARATOR
Intervention: Both exercise programs
Number of subjects: 28
Study 39666930 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic sequencing (GS)
Number of subjects: 276
Study 39666929 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 9
Study 39666948 — intervention group
Group type: EXPERIMENTAL
Intervention: Memo 4D intervention
Number of subjects: 166
Study 39666984 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly effective modulator therapy
Number of subjects: 0
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: aD1
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: antiphosphatidylserine-prothrombin IgG
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: lupus anticoagulant
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: antiphosphatidylserine-prothrombin IgM
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: anticardiolipin IgG
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: lupus anticoagulant positivity with aD1 and antiphosphatidylserine-prothrombin IgG
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of aD1 and antiphosphatidylserine-prothrombin IgG
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse pregnancy outcomes
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for aD1
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for antiphosphatidylserine-prothrombin IgG
Number of subjects: 265
Study 39666985 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for antiphosphatidylserine-prothrombin IgM
Number of subjects: 265
Study 39667036 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenemase-producing Enterobacter spp. infections
Number of subjects: 136
Study 39667036 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age at enrollment
Number of subjects: 136
Study 39667380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypovolaemic phlebotomy
Number of subjects: 486
Study 39667380 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 486
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 3 mg/kg intravenous
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 10 mg/kg intravenous
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 30 mg/kg intravenous
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 5 mg/kg subcutaneous
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 20 mg/kg intravenous plus VRC07-523LS 20 mg/kg
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS 5 mg/kg subcutaneous plus VRC07-523LS 5 mg/kg
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (all doses)
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS (subcutaneous)
Number of subjects: 33
Study 39667379 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT121.414.LS and VRC07-523LS (higher-dose and dual combination intravenous)
Number of subjects: 33
Study 39667975 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 81-8973 (25-50 IU/kg) at least twice weekly
Number of subjects: 82
Study 39668137 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily)
Number of subjects: 266
Study 39668137 — intervention group
Group type: COMPARATOR
Intervention: Nonplatinum chemotherapy (physician's choice of pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan)
Number of subjects: 266
Study 39668350 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-VR intervention (n=64)
Number of subjects: 128
Study 39668350 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (n=64)
Number of subjects: 128
Study 39668364 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroathletic training exercises
Number of subjects: 19
Study 39668364 — intervention group
Group type: COMPARATOR
Intervention: Traditional movement therapy
Number of subjects: 19
Study 39668486 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed 68Ga-FAPI-04 PET/CT
Number of subjects: 69
Study 39668544 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) system
Number of subjects: 131
Study 39668544 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced physicians
Number of subjects: 131
Study 39668544 — intervention group
Group type: COMPARATOR
Intervention: Experienced physicians
Number of subjects: 131
Study 39668580 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC22A1 1022C>T (CT genotype)
Number of subjects: 16
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular corticosteroid injections
Number of subjects: 354
Study 39669005 — intervention group
Group type: COMPARATOR
Intervention: Saline injections
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis by MRI
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand function by MAP-Hand questionnaire
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovitis by clinical examination and ultrasound
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of pain, function, stiffness, and health-related quality of life
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct and indirect costs
Number of subjects: 354
Study 39669005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 354
Study 39669115 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat flexible footwear (FFF) added to exercise therapy
Number of subjects: 0
Study 39669115 — intervention group
Group type: COMPARATOR
Intervention: Stable supportive shoes (SSS) added to exercise therapy
Number of subjects: 0
Study 39669537 — intervention group
Group type: EXPERIMENTAL
Intervention: GAIN-Q4
Number of subjects: 101897
Study 39669652 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild autonomous cortisol secretion (MACS) group (1 mg-DST > 1.8 µg/dL)
Number of subjects: 90
Study 39669652 — intervention group
Group type: COMPARATOR
Intervention: Non-functioning adrenal tumor group (1 mg-DST ≤ 1.8 µg/dL)
Number of subjects: 90
Study 39670007 — intervention group
Group type: EXPERIMENTAL
Intervention: Imprime PGG (4 mg/kg)
Number of subjects: 33
Study 39670171 — intervention group
Group type: EXPERIMENTAL
Intervention: CRPS patients
Number of subjects: 25
Study 39670171 — intervention group
Group type: COMPARATOR
Intervention: HHC
Number of subjects: 25
Study 39670171 — intervention group
Group type: COMPARATOR
Intervention: Mouse model of CRPS
Number of subjects: 25
Study 39670353 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper lobectomy
Number of subjects: 226
Study 39670353 — intervention group
Group type: COMPARATOR
Intervention: Lower lobectomy
Number of subjects: 226
Study 39670468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavdegalutamide (ARV-110)
Number of subjects: 0
Study 39670468 — intervention group
Group type: EXPERIMENTAL
Intervention: Bavdegalutamide (ARV-110) in combination with abiraterone
Number of subjects: 0
Study 39670468 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 0
Study 39670843 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorine 18
Number of subjects: 0
Study 39671024 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) intake (60 g of maltodextrin + fructose)
Number of subjects: 23
Study 39671076 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 269
Study 39671076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 39671157 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin extended release up to 750 mg twice daily
Number of subjects: 0
Study 39671157 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and risk factor modification (LRFM)
Number of subjects: 0
Study 39671157 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of metformin and LRFM
Number of subjects: 0
Study 39671157 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39671174 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable gp120 vaccine with GLA-SE adjuvant
Number of subjects: 0
Study 39671174 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient gp120 vaccine with GLA-SE adjuvant
Number of subjects: 0
Study 39671199 — intervention group
Group type: EXPERIMENTAL
Intervention: SINEMA intervention (system-integrated technology-enabled model of care)
Number of subjects: 998
Study 39671199 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 998
Study 39671198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact placental circulation for 180 seconds
Number of subjects: 209
Study 39671198 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord milking followed by early cord clamping (within 20 seconds of life)
Number of subjects: 209
Study 39671203 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application-based coaching (high-tech)
Number of subjects: 4852
Study 39671203 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person coaching of clinicians (high-touch)
Number of subjects: 4852
Study 39671203 — intervention group
Group type: COMPARATOR
Intervention: Posters placed in examination rooms (ASK)
Number of subjects: 4852
Study 39671266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP)
Number of subjects: 4932
Study 39671266 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment (control)
Number of subjects: 4932
Study 39671272 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy
Number of subjects: 441
Study 39671272 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 441
Study 39671525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injection + dry needling
Number of subjects: 66
Study 39671525 — intervention group
Group type: COMPARATOR
Intervention: Interlaminar epidural steroid injection + sham dry needling
Number of subjects: 66
Study 39671525 — intervention group
Group type: COMPARATOR
Intervention: Only interlaminar epidural steroid injection
Number of subjects: 66
Study 39671533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab
Number of subjects: 0
Study 39671533 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 0
Study 39671539 — intervention group
Group type: EXPERIMENTAL
Intervention: CT response score (CTRS) from deep learning radiomic biomarker in RWD Test Data Set B (n = 458)
Number of subjects: 1829
Study 39671539 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRS in Clinical Trial Data Set C (n = 54)
Number of subjects: 1829
Study 39671539 — intervention group
Group type: EXPERIMENTAL
Intervention: CTRS and eCTRS
Number of subjects: 1829
Study 39671543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1,500 mg twice a day for 48 weeks)
Number of subjects: 47
Study 39671543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 39671552 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANGII)
Number of subjects: 321
Study 39671552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 39671573 — intervention group
Group type: EXPERIMENTAL
Intervention: Active iTBS intervention (intermittent theta burst stimulation), performed daily, 5 days a week, for 2 weeks.
Number of subjects: 56
Study 39671573 — intervention group
Group type: COMPARATOR
Intervention: Sham iTBS (control group).
Number of subjects: 56
Study 39671575 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based physical activity intervention
Number of subjects: 64
Study 39671575 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 64
Study 39671585 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified Home-Based Cognitive-Nutritional (GAHOCON) training for 12 weeks (4 weeks center-based training + 8 weeks home-based training).
Number of subjects: 25
Study 39671585 — intervention group
Group type: COMPARATOR
Intervention: Control group received 4 weeks of center-based training and 8 weeks of self-revision of health educational materials.
Number of subjects: 25
Study 39671695 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg QD
Number of subjects: 0
Study 39671695 — intervention group
Group type: EXPERIMENTAL
Intervention: Etrasimod with concomitant 5-ASA
Number of subjects: 0
Study 39671695 — intervention group
Group type: COMPARATOR
Intervention: Concomitant corticosteroids (CS) only
Number of subjects: 0
Study 39671695 — intervention group
Group type: COMPARATOR
Intervention: Concomitant CS + 5-ASA
Number of subjects: 0
Study 39671752 — intervention group
Group type: EXPERIMENTAL
Intervention: CLR 131 with external beam radiation therapy (EBRT)
Number of subjects: 12
Study 39671779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decrease of circulating tumor DNA (ctDNA) ratio after one cycle of neoadjuvant chemotherapy (NACT)
Number of subjects: 188
Study 39671779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decrease of ctDNA ratio
Number of subjects: 188
Study 39671779 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable ctDNA at diagnosis (T0)
Number of subjects: 188
Study 39671779 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative ctDNA or decrease of more than 80% after one cycle of NACT (T1)
Number of subjects: 188
Study 39672082 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT PN
Number of subjects: 94
Study 39672082 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil-based PN
Number of subjects: 94
Study 39672082 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA-enriched PN
Number of subjects: 94
Study 39672101 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided e-learning program
Number of subjects: 115
Study 39672101 — intervention group
Group type: COMPARATOR
Intervention: Delayed-start control condition
Number of subjects: 115
Study 39672183 — intervention group
Group type: COMPARATOR
Intervention: RH5.1/Matrix-M delayed third-dose regimen
Number of subjects: 361
Study 39672183 — intervention group
Group type: COMPARATOR
Intervention: RH5.1/Matrix-M monthly regimen
Number of subjects: 361
Study 39672183 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M (both cohorts)
Number of subjects: 361
Study 39672183 — intervention group
Group type: EXPERIMENTAL
Intervention: RH5.1/Matrix-M
Number of subjects: 361
Study 39672366 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH ≥2.0 mU/L and TPO-Ab ≥30 U/mL (exposed)
Number of subjects: 1578
Study 39672366 — intervention group
Group type: COMPARATOR
Intervention: TSH <2.0 mU/L and TPO-Ab <30 U/mL (unexposed)
Number of subjects: 1578
Study 39672515 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated intensity modulated proton therapy (IMPT) with 67.5 Gy to prostate/seminal vesicles and 45 Gy to pelvic lymph nodes in 25 daily fractions, all received androgen deprivation therapy.
Number of subjects: 56
Study 39672574 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary posterior tracheopexy (PPT)
Number of subjects: 78
Study 39672574 — intervention group
Group type: COMPARATOR
Intervention: No primary posterior tracheopexy (no-PPT)
Number of subjects: 78
Study 39672576 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee osteotomy combined with meniscal allograft transplantation (MAT)
Number of subjects: 52